AV-block and conduction slowing prevail over TdP arrhythmias in the methoxamine-sensitized pro-arrhythmic rabbit model

Journal of Cardiovascular Electrophysiology

Volumn 26, Issue 1, 2015, Pages 82-89

  Varkevisser, Rosanne ^a   Vos, Marc A ^a   Beekman, Jet D ^a   Tieland, Ralph G ^a   Van Der Heyden, Marcel A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

anesthesia; conduction block; dofetilide; drug safety; methoxamine rabbit model; Torsade de Pointes

Indexed keywords

DOFETILIDE; FLUNARIZINE; HYPNORM; ISOFLURANE; KETAMINE; METHOXAMINE; MIDAZOLAM; PROPOFOL; XYLAZINE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; PHENETHYLAMINE DERIVATIVE; SULFONAMIDE;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CONTROLLED STUDY; DRUG INFUSION; DRUG SAFETY; DRUG SENSITIVITY; EXPERIMENTAL ATRIOVENTRICULAR BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART REPOLARIZATION; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; RABBIT MODEL; SECOND DEGREE ATRIOVENTRICULAR BLOCK; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE; ACTION POTENTIAL; ANIMAL; ATRIOVENTRICULAR BLOCK; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HEART FUNCTION TEST; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; RABBIT; TIME; TORSADES DE POINTES;

ACTION POTENTIALS; ANESTHETICS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIOVENTRICULAR BLOCK; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FLUNARIZINE; HEART CONDUCTION SYSTEM; HEART RATE; METHOXAMINE; PHENETHYLAMINES; RABBITS; SULFONAMIDES; TIME FACTORS; TORSADES DE POINTES;

EID: 84921485942     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12533     Document Type: Article

References (42)

1. Carlsson L, Almgren O, Duker G,: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 1990; 16: 276-285.
2. Carlsson L,: The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Ther 2008; 119: 160-167.
3. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR Jr,: Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharmacol Exp Ther 1996; 276: 637-646.
4. Farkas A, Coker SJ,: Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. Eur J Pharmacol 2002; 449: 143-153.
5. Farkas AS, Rudas L, Makra P, Csik N, Lepran I, Forster T, Csanady M, Papp JG, Varro A, Farkas A,: Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in alpha(1) -adrenoceptor-stimulated, anaesthetized rabbits. Br J Pharmacol 2010; 161: 1477-1495.
6. Batey AJ, Coker SJ,: Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol 2002; 135: 1003-1012.
7. Buchanan LV, Kabell G, Brunden MN, Gibson JK,: Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharm 1993; 22: 540-549.
8. Farkas A, Lepran I, Papp JG,: Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharm 2002; 39: 287-297.
9. Vincze D, Farkas AS, Rudas L, Makra P, Csik N, Lepran I, Forster T, Csanady M, Papp JG, Varro A, Farkas A,: Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits. Br J Pharmacol 2008; 153: 75-89.
10. Lu HR, Remeysen P, De Clerck F,: Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharm 2000; 36: 728-736.
11. Lu HR, Remeysen P, Somers K, Saels A, De Clerck F,: Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 2001; 12: 538-545.
12. Lu HR, Van Ammel K, Vlaminckx E, De Clerck F,: QT and JT dispersion in the drug-induced long QT syndrome in anaesthetized rabbits is accurately detected by a three-lead surface ECG measurement. J Pharmacol Toxicol Methods 2004; 49: 71-79.
13. Inaba H, Hayami N, Ajiki K, Kunishima T, Watanabe H, Tsutsui K, Yamagishi N, Yamagishi S, Sugiura A, Mikamo T, Murakawa Y,: Deep anesthesia suppresses ventricular tachyarrhythmias in rabbit model of the acquired long QT syndrome. Circ J 2011; 75: 89-93.
14. Tsutsui K, Hayami N, Kunishima T, Sugiura A, Mikamo T, Kanamori K, Yamagishi N, Yamagishi S, Watanabe H, Ajiki K, Murakawa Y,: Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome. Circ J 2012; 76: 2343-2347.
15. Nalos L, Varkevisser R, Jonsson MK, Houtman MJ, Beekman JD, van der Nagel R, Thomsen MB, Duker G, Sartipy P, de Boer TP, Peschar M, Rook MB, van Veen TA, van der Heyden MA, Vos MA,: Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br J Pharmacol 2012; 165: 467-478.
16. Dunnink A, van Opstal JM, Oosterhoff P, Winckels SK, Beekman JD, van der Nagel R, Cora Verduyn S, Vos MA,: Ventricular remodelling is a prerequisite for the induction of dofetilide-induced torsade de pointes arrhythmias in the anaesthetized, complete atrio-ventricular-block dog. Europace 2012; 14: 431-436.
17. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, Volders PG, Vos MA,: Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004; 110: 2453-2459.
18. Dessertenne F,: [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 1966; 59: 263-272.
19. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G,: Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993; 27: 2186-2193.
20. Detre E, Thomsen MB, Beekman JD, Petersen KU, Vos MA,: Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: Confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. Br J Pharmacol 2005; 145: 397-404.
21. Farkas A, Dempster J, Coker SJ,: Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model. Br J Pharmacol 2008; 154: 958-970.
22. Brunner M, Peng X, Liu GX, Ren XQ, Ziv O, Choi BR, Mathur R, Hajjiri M, Odening KE, Steinberg E, Folco EJ, Pringa E, Centracchio J, Macharzina RR, Donahay T, Schofield L, Rana N, Kirk M, Mitchell GF, Poppas A, Zehender M, Koren G,: Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest 2008; 118: 2246-2259.
23. Odening KE, Hyder O, Chaves L, Schofield L, Brunner M, Kirk M, Zehender M, Peng X, Koren G,: Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. Am J Physiol Heart Circ Physiol 2008; 295: H2264-H2272.
24. Odening KE, Kirk M, Brunner M, Ziv O, Lorvidhaya P, Liu GX, Schofield L, Chaves L, Peng X, Zehender M, Choi BR, Koren G,: Electrophysiological studies of transgenic long QT type 1 and type 2 rabbits reveal genotype-specific differences in ventricular refractoriness and His conduction. Am J Physiol Heart Circ Physiol 2010; 299: H643-H655.
25. Howarth FC, Levi AJ, Hancox JC,: Characteristics of the delayed rectifier K current compared in myocytes isolated from the atrioventricular node and ventricle of the rabbit heart. Pflugers Arch 1996; 431: 713-722.
26. Sato N, Tanaka H, Habuchi Y, Giles WR,: Electrophysiological effects of ibutilide on the delayed rectifier K(+) current in rabbit sinoatrial and atrioventricular node cells. Eur J Pharmacol 2000; 404: 281-288.
27. Dumaine R, Cordeiro JM,: Comparison of K+ currents in cardiac Purkinje cells isolated from rabbit and dog. J Mol Cell Cardiol 2007; 42: 378-389.
28. Lu HR, Marien R, Saels A, De Clerck F,: Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 2001; 12: 93-102.
29. Han C, Pogwizd SM, Killingsworth CR, Zhou Z, He B,: Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart. Heart Rhythm 2013; 10: 1509-1515.
30. Thomsen MB, Matz J, Volders PG, Vos MA,: Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006; 112: 150-170.
31. Varkevisser R, Wijers SC, van der Heyden MA, Beekman JD, Meine M, Vos MA,: Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo. Heart Rhythm 2012; 9: 1718-1726.
32. Carlsson L, Andersson B, Linhardt G, Lofberg L,: Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharm 2009; 54: 82-89.
33. Jacobson I, Carlsson L, Duker G,: Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. J Pharmacol Toxicol Methods 2011; 63: 40-46.
34. Carlsson L, Abrahamsson C, Drews L, Duker G,: Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1992; 85: 1491-1500.
35. Carlsson L, Drews L, Duker G,: Rhythm anomalies related to delayed repolarization in vivo: Influence of sarcolemmal Ca2+ entry and intracellular Ca2+ overload. J Pharmacol Exp Ther 1996; 279: 231-239.
36. Carlsson L, Drews L, Duker G, Schiller-Linhardt G,: Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 1993; 267: 1076-1080.
37. Wu Y, Carlsson L, Liu T, Kowey PR, Yan GX,: Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 2005; 16: 898-904.
38. Farkas A, Lepran I, Papp JG,: Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits. Eur J Pharmacol 1998; 346: 245-253.
39. Gbadebo TD, Trimble RW, Khoo MS, Temple J, Roden DM, Anderson ME,: Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 2002; 105: 770-774.
40. Tan HL, Hou CJ, Sung RJ,: Effects of adenosine A1-receptor activation on torsade de pointes in rabbits. Cardiovasc Drugs Ther 1999; 13: 441-447.
41. White CM, Xie J, Chow MS, Kluger J,: Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 1999; 19: 635-640.
42. Diness TG, Yeh YH, Qi XY, Chartier D, Tsuji Y, Hansen RS, Olesen SP, Grunnet M, Nattel S,: Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res 2008; 79: 61-69.